Volume 1, Issue 3 (Journal of Clinical and Basic Research(JCBR) 2017)                   jcbr 2017, 1(3): 1-7 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Azarhoush R, Cheraghali R, Saffarian M S, Mehravar F. Expression of Bcl-2 and p53 protein in Stomach Cancer Patients and Association with Clinicopathological Factors. jcbr. 2017; 1 (3) :1-7
URL: http://jcbr.goums.ac.ir/article-1-70-en.html
Abstract:   (2580 Views)
Introduction: Stomach cancer is one of the most common cancers worldwide. Bcl-2 and p53 appear to be important biomarkers in patients with stomach cancer. In this study, we investigated the expression of Bcl-2 and p53 proteins and its association with clinicopathological factors in 67 Iranian stomach cancer patients over a 5-year period (2010-2015). Material and Methods: In this cross sectional study, the expression of the Bcl-2 and p53 protein was determined using immunohistochemistry, and the pathological features of tumors were evaluated. Results: The expression of Bcl-2 and p53 proteins was detected in 47% and 48% of the patients, respectively. Of the 67 patients, 39 patients had intestinal-type gastric adenocarcinoma, and 57 patients had grade І and ΙΙ. There was a statistically significant association between Bcl-2 and p53 expressions (P=0.04). Conclusions: There is an association between Bcl-2 and p53 protein expressions in patients with stomach cancer. Bcl-2 and p53 protein expressions are more frequent in high-grade tumors. Bcl-2 and p53 expression might play an important role in the early development and phenotypic differentiation of gastric carcinomas, but not so in tumor progression.
Full-Text [PDF 374 kb]   (627 Downloads)    
Article Type: Research | Subject: Basic medical sciences
Received: 2017/07/25 | Accepted: 2017/11/20 | Published: 2017/11/28

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: a cancer journal for clinicians. 2016;66(1):7-30. [DOI:10.3322/caac.21332]
2. Amori N, Aghajani M, Asgarian F, Jazayeri M. Epidemiology and trend of common cancers in Iran (2004–2008). European journal of cancer care. 2017;26(5):1-6. [DOI:10.1111/ecc.12449]
3. Almasi Z, Rafiemanesh H, Salehiniya H. Epidemiology characteristics and trends of incidence and morphology of stomach cancer in Iran. Asian Pacific Journal of Cancer Prevention. 2015;16(7):2757-61. [DOI:10.7314/APJCP.2015.16.7.2757]
4. Schumacher SE, Shim BY, Corso G, Ryu M-H, Kang Y-K, Roviello F, et al. Somatic copy number alterations in gastric adenocarcinomas among Asian and Western patients. PloS one. 2017;12(4):e0176045. [DOI:10.1371/journal.pone.0176045]
5. Xu AG, Li SG, Liu JH, Gan AH. Function of apoptosis and expression of the proteins Bcl-2, p53 and C-myc in the development of gastric cancer. World Journal of gastroenterology. 2001;15;7(3):403.
6. Zheng Y, Wang L, Zhang J-P, Yang J-Y, Zhao Z-M, Zhang X-Y. Expression of p53, c-erbB-2 and Ki67 in intestinal metaplasia and gastric carcinoma. World journal of gastroenterology. 2010;16(3):339. [DOI:10.3748/wjg.v16.i3.339]
7. Drebber U, Baldus SE, Nolden B, Grass G, Bollschweiler E, Dienes HP, et al. The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation. Oncology reports. 2008;19(6):1477-83.
8. Martin HM, Filipe MI, Morris RW, Lane DP, Silvestre F. p53 expression and prognosis in gastric carcinoma. International journal of cancer. 1992;50(6):859-62. [DOI:10.1002/ijc.2910500604]
9. Aizawa K, Ueki K, Suzuki S, Yabusaki H, Kanda T, Nishimaki T, et al. Apoptosis and Bbcl-2 expression in gastric carcinomas: correlation withclinicopathological variables, p53 expression, cell proliferation and prognosis. International journal of oncology. 1999;14(1):85-176. [DOI:10.3892/ijo.14.1.85]
10. Lee HK, Lee HS, Yang HK, Kim WH, Lee KU, Choe KJ, , et al. Prognostic significance of Bcl-2 and p53 expression in gastric cancer. International journal of colorectal disease. 2003;18(6):518-25. [DOI:10.1007/s00384-003-0491-2]
11. Sjögren S, Inganäs M, Norberg T, Lindgren A, Nordgren H, Holmberg L, et al. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. Journal of the National Cancer Institute. 1996;88(3-4):173-82. [DOI:10.1093/jnci/88.3-4.173]
12. Elsaleh H, Powell B, McCaul K, Grieu F, Grant R, Joseph D, et al. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clinical cancer research. 2001;7(5):1343-9.
13. Zhao D-p, Ding X-w, Peng J-p, Zheng Y-x, Zhang S-z. Prognostic significance of bcl-2 and p53 expression in colorectal carcinoma. Journal of Zhejiang University Science B. 2005;6(12):1163-9. [DOI:10.1631/jzus.2005.B1163]
14. Liu H-F, Liu W-W, Fang D-C, Men R-P. Expression of bcl-2 protein in gastric carcinoma and its significance. World journal of gastroenterology. 1998;4(3):228. [DOI:10.3748/wjg.v4.i3.228]
15. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta pathologica et microbiologica Scandinavica. 1965;64:31-49. [DOI:10.1111/apm.1965.64.1.31]
16. Karim S, Ali A. Correlation of p53 over-expression and alteration in p53 gene detected by polymerase chain reaction-single strand conformation polymorphism in adenocarcinoma of gastric cancer patients from India. World Journal of Gastroenterology. 2009;15(11):1381. [DOI:10.3748/wjg.15.1381]
17. Renault B, Van Den Broek M, Fodde R, Wijnen J, Pellegata NS, Amadori D, et al. Base transitions are the most frequent genetic changes at p53 in gastric cancer. Cancer research. 1993;53(11):2614-7.
18. Ando K, Oki E, Zhao Y, Ikawa-Yoshida A, Kitao H, Saeki H, et al. Mortalin is a prognostic factor of gastric cancer with normal p53 function. Gastric Cancer. 2014;17(2):255-62. [DOI:10.1007/s10120-013-0279-1]
19. Li N, Deng W, Ma J, Wei B, Guo K, Shen W, et al. Prognostic evaluation of Nanog, Oct4, Sox2, PCNA, Ki67 and E-cadherin expression in gastric cancer. Medical oncology. 2015;32(1):433. [DOI:10.1007/s12032-014-0433-6]
20. Karim S. Clinicopathological and p53 gene alteration comparison between young and older patients with gastric cancer. Asian Pacific Journal of Cancer Prevention. 2014;15(3):1375-9. [DOI:10.7314/APJCP.2014.15.3.1375]
21. Azarhoush R, Keshtkar AA, Amiriani T, Kazemi-Nejad V. Relationship between p53 expression and gastric cancers in cardia and antrum. Archives of Iranian medicine. 2008;11(5):502-6.
22. Lauwers GY, Scott GV, Karpeh MS. Immunohistochemical evaluation of bcl‐2 protein expression in gastric adenocarcinomas. Cancer. 1995;75(9):2209-13. https://doi.org/10.1002/1097-0142(19950501)75:9<2209::AID-CNCR2820750904>3.0.CO;2-M [DOI:10.1002/1097-0142(19950501)75:93.0.CO;2-M]
23. Li X, Hao Y, Zou J, Yang J, Geng J. Relationship between C-myc and Bcl-2 alterations and biological behavior and apoptosis in gastric cancer. Xin Xiaohuabingxue Zazhi. 1997;5:773-4.
24. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, et al. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. JNCI: Journal of the National Cancer Institute. 1994;86(7):499-504. [DOI:10.1093/jnci/86.7.499]
25. Herod JJO, Eliopoulos AG, Warwick J, Niedobitek G, Young LS, Kerr DJ. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Research. 1996;56(9):2178-84.
26. Zaanan A, Cuilliere-Dartigues P, Guilloux A, Parc Y, Louvet C, De Gramont A, et al. Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Annals of oncology. 2010;21(4):772-80. [DOI:10.1093/annonc/mdp383]

Add your comments about this article : Your username or Email:

© 2021 All Rights Reserved | Journal of Clinical and Basic Research

Designed & Developed by : Yektaweb

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0).